|Articles|October 1, 2003

HELIX BIOMEDIX PEPTIDE STUDIED

Helix BioMedix completed a preliminary study designed to evaluate the efficacy of one the company's proprietary peptides, HB64, in reducing severity of mild to moderate acne symptoms.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME